|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
rs187960998 in miR-211 was highly associated with a decreased risk of CC in the Chinese population by deregulating a tumor suppressive gene CHD5.
|
30655677 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CHD5 is a conventional tumour-suppressing gene in many tumours.
|
29907144 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression levels of CHD5 gene in 59 tumor and corresponding non-cancerous lung tissue samples were analyzed by qRT-PCR and the methylation status of the promoter region was investigated by methylation specific PCR (MS-PCR).
|
28400267 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, CHD5 mutations appear to be rare in RCC tumors through genome database mining.
|
26943038 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutation of the remaining CHD5 allele is rare in these tumors, yet expression is very low or absent, so expression is likely regulated by epigenetic mechanisms.
|
26895110 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chromodomain helicase DNA binding protein 5 (CHD5) acts as a tumor suppressor in many cancers.
|
26517514 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Recurrent alterations at relapse included mutations in the putative CHD5 neuroblastoma tumor suppressor, chromosome 9p losses, DOCK8 mutations, inactivating mutations in PTPN14 and a relapse-specific activity pattern for the PTPN14 target YAP.
|
26121086 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chromodomain-helicase DNA binding protein 5 (CHD5) is an important tumor suppressor gene deleted from 1p36.31 in neuroblastomas (NBs).
|
26245651 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CHD5 is down-regulated in several cancers, including leukemia and is responsible for tumor generation and progression.
|
24454811 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CHD5 likely acts as a tumor-suppressor gene in early colorectal carcinogenesis.
|
24243398 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, low CHD5 expression is strongly associated with unfavorable clinical and biologic features as well as outcome in neuroblastomas and many other tumor types.
|
24419087 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of the chromatin remodeling ATPase CHD5 has been linked to the progression of neuroblastoma tumors, yet the underlying mechanisms behind the tumor suppressor role of CHD5 are unknown.
|
25247294 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings demonstrate that CHD5 is a potential tumour suppressor gene epigenetically silenced in HCC.
|
24529164 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These findings provide insights into the regulatory role of CHD5 during neurogenesis and suggest how inactivation of this candidate tumor suppressor might contribute to neuroblastoma.
|
23948251 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chd5 requires PHD-mediated histone 3 binding for tumor suppression.
|
23318260 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Clonogenicity and tumor growth were abrogated in A549 and H1299 cells upon restoration of CHD5 expression.
|
22186629 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We identified the chromatin-remodeling gene CHD5 as a tumor suppressor gene that maps to 1p36.31.
|
22294723 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We find CHD5, a known tumor suppressor regulating p53 activity, as a target of JMJD2A.
|
23168260 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CHD5 protein expression was also reduced in breast cancer, and lack of CHD5 expression significantly correlated with higher tumor stage, ER/PR-negativity, HER2 positivity, distant metastasis and worse patient survival (P ≤ 0.01).
|
22569290 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Similar to other cancer types, some typical tumor suppressor genes (TSGs), such as P53 and CHD5 are silenced in NB because of high methylation at promoter zones.
|
22960751 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5.
|
22235338 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this Caucasian population, endometriosis seems to be associated with the tumor-suppressor gene CHD5.
|
22910690 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest that CHD5 is a tumor suppressor gene that is epigenetically downregulated in LSCC.
|
21636313 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, strong evidence has been reported that CHD5 is a tumour suppressor gene in this region.
|
21250965 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The correlation of CHD5 expression to clinicopathological features of the tumor was analyzed.
|
21860208 |
2011 |